TREMFYA (guselkumab) treatment of active psoriasis arthritis (PsA): positive advice has been received from CHMP.

Active psoriasis arthritis (PsA) is a chronic, immuno-mediated inflammatory disease characterized by joint damage and inflammation in addition to dermatitis, mastitis, axon disease and psoriasis-related skin lesions.
there is no cure, and it is estimated that up to a third of Europe's 14 million psoriasis patients will continue to develop PSA.
IL-23 is an important driver of the pathogenesis of inflammatory diseases such as PsA and psoriasis.
Guselkumab is a monoclonal antibody that selectively binds to the p19 sub-base of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor.
The European Medicines Agency (EMA) Human Medicines Commission (CHMP) has recommended expanding the use of TREMFYA (guselkumab) to treat adult patients with active psoriasis arthritis (PsA), the company announced.
Guselkumab is currently approved in the European Union for the treatment of systemic moderate to severe plaque-like psoriasis.
Iain McInnes, of the University of Glasgow, said: "Psoriasis arthritis is a disease that is currently incurable.
requires long-term control of the symptoms of joints, skin and soft tissues.
if approved, guselkumab will be our new treatment for the disease."
.